Drug Profile
GM 1445
Latest Information Update: 29 Aug 2007
Price :
$50
*
At a glance
- Originator Glycomed
- Class Antithrombotics; Vascular disorder therapies
- Mechanism of Action Glycosaminoglycan stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Deep vein thrombosis
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 03 Jun 1997 No-Development-Reported for Deep vein thrombosis in USA (Unknown route)
- 04 May 1995 Preclinical development for Deep vein thrombosis in USA (Unknown route)